WEARING A MASK IS STILL REQUIRED IN PATIENT AREAS AT SUNNYBROOK. READ OUR VISITOR GUIDELINES »

Cancer trials
Hospital  >  Care Programs  >  Odette Cancer Program  >  Clinical trials

Trial details

Men with Prostate Cancer on Active Surveillance -- An update of the Odette Cancer Centre Experience

To find out more about this trial and your cancer treatment options, please speak with your doctor.

Trial short name: Biobank

Official title: Men with Prostate Cancer on Active Surveillance -- An update of the Odette Cancer Centre Experience

Principal Investigator: Dr. Andrew Loblaw

Cancer type: Genitourinary
Cancer location: Prostate
Disease stage: Early Cancer
Trial phase: Other
Intervention: Other: Registry with collection of samples (biopsy)

Registration #: N/A

Trial description:
The purpose of this study is to create a collection of samples from prostate cancer patients. Patients who are diagnosed with prostate cancer, have received or will be receiving treatment, are at any stage and who meet a certain criteria may be able to participate. Patients will be registered on the biobank and biospecimen and medical data will be collected prior to receiving treatment. The aim of this biobank is to identify common factors which may be associated with prostate cancer. No treatment will be provided to patients as part of this study.

Inclusion criteria: Patients from the following 3 groups are eligible to take part in this study: • Men who are considered intermediate to high risk prostate cancer patients with advanced and potentially aggressive disease (Gleason Score 7 or greater) who will be receiving active treatment (surgery, radiation, hormones or chemotherapy). • Men who are cancer-free, with benign conditions such as prostate hyperplasia (also known as “BPH”) who are not suspected to have prostate cancer based on low PSA levels and/or negative prostate biopsy. • Men with early stage prostate cancer that are being managed with Active Surveillance, who are followed by regular PSA measurements and prostate biopsies.